Cardiac toxicity with monoclonal antibodies therapy

  • Haitham Mazek Department of Internal Medicine, Texas Tech University Health Sciences Center
  • Rashmi Verma
  • Jason Wischmeyer
Keywords: cancer therapy, monoclonal antibodies, cardiac toxicity, pericardial effusion


Breast cancers which overexpress the human epidermal growth factor receptor 2 (HER2) proteins generally have poor prognosis. Trastuzumab is a monoclonal antibody which inhibits HER-2 activation and has been shown to be an effective therapy for women with breast cancers that overexpress HER2 proteins. The most important side effect of trastuzumab is cardiotoxicity. We report a patient with left ventricular dysfunction and pericardial effusion after treatment with pertuzumab and trastuzumab.


Download data is not yet available.
How to Cite
Mazek, H., Verma, R., & Wischmeyer, J. (2015). Cardiac toxicity with monoclonal antibodies therapy. The Southwest Respiratory and Critical Care Chronicles, 3(11), 52-54. Retrieved from